|
NZ618298A
(en)
|
2001-11-13 |
2015-04-24 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
EP2292780B1
(en)
|
2003-09-30 |
2017-08-23 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
|
CN101528916B
(zh)
|
2006-04-28 |
2013-09-04 |
宾夕法尼亚大学托管会 |
规模可调的aav生产方法
|
|
EP2037892B1
(en)
*
|
2006-06-19 |
2015-03-18 |
Asklepios Biopharmaceutical, Inc. |
Modified factor viii and factor ix genes and vectors for gene therapy
|
|
EP3492596A1
(en)
|
2007-04-09 |
2019-06-05 |
University of Florida Research Foundation, Inc. |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
US20120093772A1
(en)
|
2008-05-20 |
2012-04-19 |
Alan Horsager |
Vectors for delivery of light sensitive proteins and methods of use
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
WO2010127097A1
(en)
*
|
2009-04-30 |
2010-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
WO2011038187A1
(en)
|
2009-09-25 |
2011-03-31 |
The Trustees Of The University Of Pennsylvania |
Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom
|
|
SG183929A1
(en)
|
2010-03-29 |
2012-10-30 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US9102949B2
(en)
|
2010-04-23 |
2015-08-11 |
University Of Massachusetts |
CNS targeting AAV vectors and methods of use thereof
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP2561075B1
(en)
|
2010-04-23 |
2018-06-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
WO2012007458A1
(en)
|
2010-07-12 |
2012-01-19 |
Universidad Autónoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
JP5704361B2
(ja)
*
|
2010-10-27 |
2015-04-22 |
学校法人自治医科大学 |
神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
|
WO2012145572A1
(en)
|
2011-04-20 |
2012-10-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
|
EP3318634A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
|
|
DK2699270T3
(en)
|
2011-04-22 |
2017-10-02 |
Univ California |
ADENO-ASSOCIATED VIRUS VIRUSES WITH VARIANT CAPSID AND METHODS FOR USING IT
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
CA2864879C
(en)
*
|
2012-02-17 |
2021-07-20 |
The Children's Hospital Of Philadelphia |
Aav vector compositions and methods for gene transfer to cells, organs and tissues
|
|
ES2862912T3
(es)
*
|
2012-04-18 |
2021-10-08 |
Childrens Hospital Philadelphia |
Composición y procedimientos para la transferencia genética de alta eficiencia utilizando variantes de cápside de VAA
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
TWI702955B
(zh)
|
2012-05-15 |
2020-09-01 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
|
|
PT2879719T
(pt)
|
2012-08-01 |
2018-10-08 |
Ohio State Innovation Foundation |
Administração intratecal do vírus adeno-associado 9 recombinante
|
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
|
PL2900686T3
(pl)
|
2012-09-28 |
2021-01-25 |
The University Of North Carolina At Chapel Hill |
Wektory aav ukierunkowane na oligodendrocyty
|
|
HRP20201063T1
(hr)
|
2013-03-15 |
2020-11-27 |
The Trustees Of The University Of Pennsylvania |
Pripravci za liječenje mpsi
|
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
|
CN105408486B
(zh)
*
|
2013-05-21 |
2020-07-14 |
佛罗里达大学研究基金会有限公司 |
衣壳修饰的raav3载体组合物以及在人肝癌基因治疗中的用途
|
|
ES2897508T3
(es)
|
2013-05-31 |
2022-03-01 |
Univ California |
Variantes de virus adenoasociados y métodos de uso de las mismas
|
|
IL297919A
(en)
*
|
2013-07-22 |
2023-01-01 |
Childrens Hospital Philadelphia |
Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
US20160369298A1
(en)
|
2013-09-26 |
2016-12-22 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
|
EP3054995A1
(en)
*
|
2013-10-07 |
2016-08-17 |
Kiromic, LLC |
Compositions and methods for treating cardiovascular diseases using disease-specific promoter
|
|
CN115141258B
(zh)
|
2013-10-11 |
2025-05-20 |
马萨诸塞眼科耳科诊所 |
预测祖先病毒序列的方法及其用途
|
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
CA2939950C
(en)
|
2014-03-09 |
2023-08-22 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
|
|
JP6689249B2
(ja)
|
2014-03-17 |
2020-05-20 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
錐体細胞における増強された遺伝子発現のための組成物および方法
|
|
AU2015231294B2
(en)
|
2014-03-18 |
2020-10-29 |
University Of Massachusetts |
rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
JP6741590B2
(ja)
|
2014-04-25 |
2020-08-19 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
コレステロールレベルを低下させるためのｌｄｌｒ変異体および組成物中でのそれらの使用
|
|
JP6983511B2
(ja)
|
2014-04-25 |
2021-12-17 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
脳中の転移乳癌および他の癌を処置するための方法および組成物
|
|
PE20170260A1
(es)
|
2014-05-02 |
2017-04-12 |
Genzyme Corp |
Vectores de aav para la terapia genica de la retina y el snc
|
|
PT3142750T
(pt)
|
2014-05-13 |
2020-09-22 |
Univ Pennsylvania |
Composições que compreendem aav expressando construções de anticorpos duplos e suas utilizações
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
ES2993915T3
(en)
*
|
2014-08-13 |
2025-01-13 |
Childrens Hospital Philadelphia |
An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders
|
|
CA2960912A1
(en)
|
2014-09-16 |
2016-03-24 |
Universitat Autonoma De Barcelona |
Adeno-associated viral vectors for the gene therapy of metabolic diseases
|
|
WO2016054557A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Novel high efficiency library-identified aav vectors
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
CA2964272A1
(en)
|
2014-10-21 |
2016-04-28 |
Guangping Gao |
Recombinant aav variants and uses thereof
|
|
RU2716991C2
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
CN112410339A
(zh)
|
2014-11-14 |
2021-02-26 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
RU2716422C2
(ru)
|
2014-11-14 |
2020-03-11 |
Вояджер Терапьютикс, Инк. |
Композиции и способы лечения бокового амиотрофического склероза (als)
|
|
KR20240063169A
(ko)
|
2014-11-21 |
2024-05-10 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
중추 신경계에 표적화된 aav 벡터
|
|
HK1245326A1
(zh)
|
2014-12-12 |
2018-08-24 |
Voyager Therapeutics, Inc. |
用於生产scaav的组合物和方法
|
|
CA2967468A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
|
EP3242945B1
(en)
|
2015-01-07 |
2021-09-01 |
Universitat Autònoma de Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
AU2016226289B2
(en)
|
2015-03-02 |
2021-04-29 |
Adverum Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
PT3268024T
(pt)
|
2015-03-10 |
2020-12-09 |
Univ Columbia |
Construtos de vetor viral recombinante glut1 adeno associado e métodos relacionados para restaurar a expressão de glut1
|
|
US10883117B2
(en)
|
2015-03-24 |
2021-01-05 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
WO2016160761A2
(en)
*
|
2015-03-30 |
2016-10-06 |
Boehringer Ingelheim Vetmedica, Inc. |
Pcv2 orf2 carrier platform
|
|
WO2016176191A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
|
CA2985223A1
(en)
|
2015-05-07 |
2016-11-10 |
Massachusetts Eye And Ear Infirmary |
Methods of delivering an agent to the eye
|
|
MA48852A
(fr)
|
2015-05-13 |
2020-04-01 |
Univ Pennsylvania |
Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
|
|
IL256517B2
(en)
|
2015-06-23 |
2024-06-01 |
Childrens Hospital Philadelphia |
Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
ES3009026T3
(en)
|
2015-07-22 |
2025-03-25 |
Univ Duke |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
JP7166168B2
(ja)
|
2015-07-30 |
2022-11-07 |
マサチューセッツ アイ アンド イヤー インファーマリー |
祖先ウイルス配列およびその使用
|
|
IL257105B
(en)
|
2015-07-31 |
2022-09-01 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
CN108368521A
(zh)
|
2015-08-06 |
2018-08-03 |
宾夕法尼亚州大学信托人 |
Glp-1和其在用于治疗代谢疾病的组合物中的用途
|
|
EA201890565A1
(ru)
|
2015-08-25 |
2019-04-30 |
Дьюк Юниверсити |
Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз
|
|
HK1257024A1
(zh)
|
2015-08-31 |
2019-10-11 |
宾夕法尼亚大学 |
用於治疗伴侣动物的aav-epo
|
|
IL258024B2
(en)
|
2015-09-24 |
2023-03-01 |
Univ Pennsylvania |
A preparation and method for the treatment of a complement-mediated disease
|
|
US11273227B2
(en)
|
2015-10-09 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating Stargardt's disease and other ocular disorders
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
CA3002980A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
DK3364997T5
(da)
|
2015-10-22 |
2024-09-30 |
Univ Massachusetts |
Aspartoacylase genterapi til behandling af canavans sygdom
|
|
US12188037B2
(en)
*
|
2015-10-22 |
2025-01-07 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial AAV3 capsid library
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
US11135313B2
(en)
*
|
2015-10-28 |
2021-10-05 |
The Trustees Of The University Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
|
US10983110B2
(en)
|
2015-12-02 |
2021-04-20 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
|
EP3387117B1
(en)
|
2015-12-11 |
2022-11-23 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
KR102794870B1
(ko)
|
2015-12-11 |
2025-04-10 |
매사추세츠 아이 앤드 이어 인퍼머리 |
핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법
|
|
MX2018007080A
(es)
|
2015-12-11 |
2018-11-12 |
Univ Pennsylvania |
Terapia genica para tratar hipercolesterolemia familiar.
|
|
CA3007330A1
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of crigler-najjar syndrome
|
|
EP3795180B1
(en)
|
2015-12-14 |
2025-11-05 |
The Trustees of The University of Pennsylvania |
Gene therapy for ocular disorders
|
|
US11124546B2
(en)
*
|
2015-12-14 |
2021-09-21 |
The University Of North Carolina At Chapel Hill |
Modified capsid proteins for enhanced delivery of parvovirus vectors
|
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
|
CA3011939A1
(en)
*
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
MA43968A
(fr)
|
2016-02-03 |
2018-12-12 |
Univ Pennsylvania |
Thérapie génique pour traiter la mucopolysaccharidose de type i
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
SG11201808176TA
(en)
|
2016-04-15 |
2018-10-30 |
The Trustees Of The Univ Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
IL262207B1
(en)
|
2016-04-15 |
2025-09-01 |
Univ Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
SG11201808812RA
(en)
|
2016-04-15 |
2018-11-29 |
Univ Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
|
WO2017184463A1
(en)
|
2016-04-17 |
2017-10-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
DK4206216T3
(da)
|
2016-05-13 |
2025-12-01 |
4D Molecular Therapeutics Inc |
Adeno-associerede virusvarianter og fremgangsmåder til brug deraf
|
|
CN109831916B
(zh)
|
2016-05-18 |
2023-07-21 |
沃雅戈治疗公司 |
治疗亨廷顿氏舞蹈病的组合物和方法
|
|
CA3252099A1
(en)
|
2016-05-18 |
2025-06-05 |
Voyager Therapeutics, Inc. |
MODULATING POLYNUCLEOTIDES
|
|
US11504435B2
(en)
|
2016-06-13 |
2022-11-22 |
The University Of North Carolina At Chapel Hill |
Optimized CLN1 genes and expression cassettes and their use
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
IL264070B2
(en)
|
2016-07-08 |
2023-03-01 |
Univ Pennsylvania |
Methods and preparations for the treatment of disorders and diseases involving rdh12
|
|
EP3487523B1
(en)
|
2016-07-19 |
2023-09-06 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
US11883470B2
(en)
|
2016-07-25 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
MX2019000962A
(es)
*
|
2016-07-26 |
2019-08-01 |
Biomarin Pharm Inc |
Novedosas proteinas de la capside del virus adenoasociado.
|
|
KR20230039779A
(ko)
|
2016-07-29 |
2023-03-21 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법
|
|
JP2019524162A
(ja)
|
2016-08-18 |
2019-09-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
モジュラーＡＡＶ送達システムによるＣＲＩＳＰＲ−Ｃａｓゲノム編集
|
|
EP3506817A4
(en)
|
2016-08-30 |
2020-07-22 |
The Regents of The University of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
EP3518985A4
(en)
*
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
|
WO2018071831A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Massachusetts |
Aav capsid designs
|
|
JP7181862B2
(ja)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
腫瘍浸潤リンパ球および治療の方法
|
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
WO2018100054A1
(en)
|
2016-12-01 |
2018-06-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
|
CN110462037A
(zh)
*
|
2017-01-30 |
2019-11-15 |
学校法人日本医科大学 |
腺相关病毒(aav)衣壳蛋白的突变体
|
|
JP2020510648A
(ja)
|
2017-02-20 |
2020-04-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
家族性高コレステロール血症を処置するための遺伝子治療
|
|
EP3585883A4
(en)
|
2017-02-21 |
2021-04-14 |
University of Florida Research Foundation, Incorporated |
MODIFIED AAV CAPSID PROTEINS AND USES THEREOF
|
|
WO2018160573A1
(en)
|
2017-02-28 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Influenza vaccines based on aav vectors
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
WO2018160582A1
(en)
|
2017-02-28 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) clade f vector and uses therefor
|
|
EP4656244A2
(en)
|
2017-03-01 |
2025-12-03 |
The Trustees of the University of Pennsylvania |
Gene therapy for ocular disorders
|
|
TW202532642A
(zh)
|
2017-04-14 |
2025-08-16 |
美商銳進科斯生物股份有限公司 |
使用由人類神經或膠細胞產生的重組人類艾杜糖醛酸鹽 (iduronate)-2-硫酸酯酶 (ids) 之黏多醣病ii之治療
|
|
US11879133B2
(en)
|
2017-04-24 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
WO2018209154A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (app)-dependence of viruses
|
|
CN108103082B
(zh)
*
|
2017-05-11 |
2021-07-13 |
北京锦篮基因科技有限公司 |
一种腺相关病毒介导的lcat基因表达载体及其用途
|
|
US11591614B2
(en)
|
2017-05-11 |
2023-02-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ceroid lipofuscinoses
|
|
US11793887B2
(en)
|
2017-05-31 |
2023-10-24 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
|
WO2018232149A1
(en)
|
2017-06-14 |
2018-12-20 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
WO2019006182A1
(en)
|
2017-06-30 |
2019-01-03 |
The Regents Of The University Of California |
VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF
|
|
JP2020530307A
(ja)
*
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス，インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
|
BR112020000063A2
(pt)
|
2017-07-06 |
2020-07-14 |
The Trustees Of The University Of Pennsylvania |
terapia gênica mediada por aav9 para tratamento de mucopolissacaridose tipo i
|
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
|
KR102850887B1
(ko)
|
2017-08-03 |
2025-08-28 |
보이저 테라퓨틱스, 인크. |
Aav의 전달을 위한 조성물 및 방법
|
|
AU2018320849A1
(en)
*
|
2017-08-25 |
2020-03-05 |
Ovid Therapeutics Inc. |
Recombinant adeno-associated vectors
|
|
CA3059995A1
(en)
|
2017-08-28 |
2019-03-07 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
NZ763018A
(en)
|
2017-09-20 |
2023-02-24 |
4D Molecular Therapeutics Inc |
Adeno-associated virus variant capsids and methods of use thereof
|
|
CA3076036A1
(en)
|
2017-09-22 |
2019-03-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
MX2020003042A
(es)
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
CN119242711A
(zh)
|
2017-10-16 |
2025-01-03 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症（als）的治疗
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
WO2019079494A1
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio, Inc. |
TREATMENT OF OCULAR DISEASES AND METASTATIC COLON CANCER WITH A VEGF TRAP WITH HUMAN POST-TRANSLATIONAL MODIFICATION
|
|
BR112020007405A2
(pt)
|
2017-10-18 |
2020-12-08 |
Regenxbio Inc. |
Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
|
|
PT3717636T
(pt)
|
2017-11-27 |
2023-05-30 |
4D Molecular Therapeutics Inc |
Cápsides variantes de vírus adeno-associado e utilização para inibir a angiogénese
|
|
AU2018375163A1
(en)
|
2017-11-30 |
2020-06-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis IIIB
|
|
JP7389744B2
(ja)
|
2017-11-30 |
2023-11-30 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉｉｉａ型のための遺伝子療法
|
|
MY207644A
(en)
|
2017-12-19 |
2025-03-07 |
Akouos Inc |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
|
US10806802B2
(en)
|
2018-01-18 |
2020-10-20 |
University Of Guelph |
Adeno-associated virus particle with mutated capsid and methods of use thereof
|
|
AU2019211465B2
(en)
|
2018-01-23 |
2022-07-21 |
Mount Spec Investments Pty Ltd |
Expression vector and method
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
PE20212076A1
(es)
|
2018-02-01 |
2021-10-26 |
Homology Medicines Inc |
Composiciones de virus adeno-asociado para restaurar la funcion del gen pah y metodos de uso de las mismas
|
|
US11306329B2
(en)
|
2018-02-19 |
2022-04-19 |
City Of Hope |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
|
CN112352050A
(zh)
*
|
2018-02-27 |
2021-02-09 |
宾夕法尼亚州大学信托人 |
新颖腺相关病毒（aav）载体、具有降低的衣壳脱酰胺化的aav载体及其用途
|
|
EP3768695A4
(en)
*
|
2018-02-27 |
2022-04-06 |
The Trustees of the University of Pennsylvania |
NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
|
|
CN112218880A
(zh)
*
|
2018-03-29 |
2021-01-12 |
阿斯克肋匹奥生物制药公司 |
逃避中和的肝趋向性重组aav6载体
|
|
EP3775266A4
(en)
|
2018-04-05 |
2021-06-30 |
Massachusetts Eye and Ear Infirmary |
METHOD OF MANUFACTURING AND USING COMBINATIONAL BAR-CODED NUCLEIC ACID LIBRARIES WITH DEFINED VARIATION
|
|
AU2019249890B2
(en)
|
2018-04-05 |
2024-10-10 |
Association Institut De Myologie |
Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism
|
|
JP7575273B2
(ja)
|
2018-04-16 |
2024-10-29 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
デュシェンヌ型筋ジストロフィーを治療するための組成物及び方法
|
|
KR20210009317A
(ko)
|
2018-04-18 |
2021-01-26 |
더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 |
미토콘드리아 dna 고갈 증후군을 포함하는 불균형 뉴클레오타이드 풀에 의해 초래된 질환에 대한 유전자 요법
|
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
|
US20210231560A1
(en)
|
2018-04-29 |
2021-07-29 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
US20210207168A1
(en)
|
2018-05-08 |
2021-07-08 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
BR112020023082A2
(pt)
|
2018-05-15 |
2021-02-09 |
Voyager Therapeutics, Inc. |
composições e métodos para o tratamento de doença de parkinson
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
US12070702B2
(en)
|
2018-06-14 |
2024-08-27 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant AAV production
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
WO2020016655A2
(en)
|
2018-07-17 |
2020-01-23 |
Helixmith Co., Ltd. |
Treatment of neuropathy with dna constructs expressing igf-1 isoforms
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
BR112021001878A2
(pt)
*
|
2018-07-31 |
2021-04-27 |
Cornell University |
métodos de terapia genética para o controle da função do órgão
|
|
JP2021533757A
(ja)
|
2018-08-10 |
2021-12-09 |
リジェネクスバイオ インコーポレイテッド |
組換えａａｖ生成のためのスケーラブルな方法
|
|
GB201813528D0
(en)
|
2018-08-20 |
2018-10-03 |
Ucl Business Plc |
Factor IX encoding nucleotides
|
|
US10842885B2
(en)
|
2018-08-20 |
2020-11-24 |
Ucl Business Ltd |
Factor IX encoding nucleotides
|
|
EP3841109A4
(en)
*
|
2018-08-21 |
2022-09-21 |
Massachusetts Eye and Ear Infirmary |
COMPOSITIONS AND METHODS TO MODULATE THE TRANSDUCTION EFFICIENCY OF ADENO-ASSOCIATED VIRUSES
|
|
CA3111076A1
(en)
|
2018-08-30 |
2020-03-05 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with myocardin and ascl1
|
|
CA3114621A1
(en)
|
2018-09-28 |
2020-04-02 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
MX2021003869A
(es)
|
2018-10-01 |
2021-09-08 |
Univ Pennsylvania |
Composiciones útiles para tratar la gangliosidosis gm1.
|
|
US12472268B2
(en)
|
2018-10-01 |
2025-11-18 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
CA3115248A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
CA3116701A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
|
EP3867412A1
(en)
|
2018-10-15 |
2021-08-25 |
REGENXBIO Inc. |
Method for measuring the infectivity of replication defective viral vectors and viruses
|
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
WO2020117898A1
(en)
|
2018-12-05 |
2020-06-11 |
Abeona Therapeutics Inc. |
Recombinant adeno-associated viral vector for gene delivery
|
|
TWI848038B
(zh)
|
2019-01-04 |
2024-07-11 |
美商奧崔基尼克斯製藥公司 |
用於治療威爾森氏症之基因療法構築體
|
|
AU2020208467A1
(en)
|
2019-01-18 |
2021-08-05 |
Voyager Therapeutics, Inc. |
Methods and systems for producing AAV particles
|
|
CA3125294A1
(en)
*
|
2019-01-23 |
2020-07-30 |
University Of Florida Research Foundation, Incorporated |
Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
|
|
CN119390787A
(zh)
|
2019-01-31 |
2025-02-07 |
俄勒冈健康与科学大学 |
用于aav衣壳的使用转录依赖性定向进化的方法
|
|
KR20210131370A
(ko)
|
2019-02-22 |
2021-11-02 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스
|
|
US20220154210A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
WO2020174369A2
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
TW202045728A
(zh)
|
2019-02-26 |
2020-12-16 |
賓州大學委員會 |
用於治療克拉培氏病之組成物
|
|
US20220154217A1
(en)
|
2019-04-01 |
2022-05-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
CN113966236A
(zh)
|
2019-04-03 |
2022-01-21 |
再生生物股份有限公司 |
眼睛病状的基因疗法
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
PL3953483T3
(pl)
|
2019-04-11 |
2024-04-22 |
Regenxbio Inc. |
Sposoby chromatografii wykluczania do charakteryzowania kompozycji rekombinowanych wirusów towarzyszących adenowirusom
|
|
MX2021012564A
(es)
|
2019-04-19 |
2022-01-18 |
Regenxbio Inc |
Formulaciones y métodos de vectores de virus adenoasociados.
|
|
CN114127088B
(zh)
*
|
2019-04-23 |
2024-05-14 |
国家医疗保健研究所 |
变体衣壳蛋白和腺相关病毒aav变体及其药物组合物
|
|
SG11202111414RA
(en)
|
2019-04-24 |
2021-11-29 |
Regenxbio Inc |
Fully-human post-translationally modified antibody therapeutics
|
|
WO2020222858A1
(en)
*
|
2019-04-27 |
2020-11-05 |
Ocugen, Inc. |
Adeno-associated virus vector mediated gene therapy for ophthalmic diseases
|
|
BR112021021502A2
(pt)
*
|
2019-04-29 |
2022-07-19 |
Univ Pennsylvania |
Capsídeos de aav e composições contendo os mesmos
|
|
MX2021013420A
(es)
|
2019-05-03 |
2022-02-03 |
Univ Pennsylvania |
Composiciones utiles en el tratamiento de leucodistrofia metacromatica.
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
US11319354B2
(en)
|
2019-07-10 |
2022-05-03 |
Masonic Medical Research Laboratory |
VGLL4 with UCP-1 cis-regulatory element and method of use thereof
|
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
RS66255B1
(sr)
*
|
2019-07-15 |
2024-12-31 |
Meiragtx Uk Ii Ltd |
Modifikovani proteini aav kapsida za lečenje artritične bolesti
|
|
WO2021021674A1
(en)
|
2019-07-26 |
2021-02-04 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
|
EP4004214A1
(en)
|
2019-07-26 |
2022-06-01 |
RegenxBio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
AU2020336314A1
(en)
|
2019-08-26 |
2022-04-07 |
Regenxbio Inc. |
Treatment of diabetic retinopathy with fully-human post-translationally modified anti-VEGF Fab
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
KR20220079857A
(ko)
|
2019-09-13 |
2022-06-14 |
루트거스, 더 스테이트 유니버시티 오브 뉴 저지 |
Aav-상용성 라미닌-링커 중합 단백질
|
|
EP4038194A1
(en)
|
2019-10-04 |
2022-08-10 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
JP2022552262A
(ja)
|
2019-10-07 |
2022-12-15 |
リジェネックスバイオ インコーポレイテッド |
アデノ随伴ウイルスベクター医薬組成物および方法
|
|
CN113518824B
(zh)
*
|
2019-10-16 |
2024-02-23 |
上海药明康德新药开发有限公司 |
新的aav变体
|
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
BR112022009895A2
(pt)
|
2019-11-28 |
2022-08-09 |
Regenxbio Inc |
Construtos de terapia de gene de microdistrofina e usos dos mesmos
|
|
AU2020398904A1
(en)
*
|
2019-12-10 |
2022-06-30 |
Homology Medicines, Inc. |
Adeno-associated virus compositions and methods of use thereof
|
|
US11981912B2
(en)
|
2019-12-10 |
2024-05-14 |
Takeda Pharma ceutical Company Limited |
Adeno associated virus vectors for the treatment of hunter disease
|
|
CA3166374A1
(en)
|
2019-12-31 |
2021-07-08 |
Swanbio Therapeutics Limited |
Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn)
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
BR112022014563A2
(pt)
|
2020-01-22 |
2022-09-13 |
Regenxbio Inc |
Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose i (mps i)
|
|
AR121201A1
(es)
|
2020-01-29 |
2022-04-27 |
Regenxbio Inc |
Tratamiento de mucopolisacaridosis iva
|
|
CA3167741A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells
|
|
US20230190966A1
(en)
|
2020-02-02 |
2023-06-22 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating gm1 gangliosidosis
|
|
CA3164714A1
(en)
|
2020-02-14 |
2021-08-19 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating cdkl5 deficiency disorder
|
|
JP2023518327A
(ja)
*
|
2020-02-25 |
2023-04-28 |
チルドレンズ・メディカル・リサーチ・インスティテュート |
アデノ随伴ウイルスカプシドポリペプチドおよびベクター
|
|
WO2021188892A1
(en)
|
2020-03-19 |
2021-09-23 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
BR112022019047A2
(pt)
|
2020-03-27 |
2022-11-01 |
UCB Biopharma SRL |
Peptídeos de domínio knob autônomos
|
|
WO2021202532A1
(en)
|
2020-03-31 |
2021-10-07 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
KR20220167380A
(ko)
*
|
2020-04-13 |
2022-12-20 |
매사추세츠 아이 앤드 이어 인퍼머리 |
코로나바이러스에 대한 백신을 제조 및 사용하는 방법
|
|
IL297200A
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics Inc |
tau binding compounds
|
|
CN116057175A
(zh)
|
2020-05-12 |
2023-05-02 |
宾夕法尼亚州大学信托人 |
可用于治疗克拉伯病的组合物
|
|
KR20230010670A
(ko)
|
2020-05-12 |
2023-01-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
이식유전자 발현의 drg-특이적 감소를 위한 조성물
|
|
WO2021231538A2
(en)
|
2020-05-13 |
2021-11-18 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
CN116801911A
(zh)
|
2020-05-13 |
2023-09-22 |
阿库斯股份有限公司 |
用于治疗slc26a4相关听力损失的组合物和方法
|
|
AU2021282257A1
(en)
|
2020-05-26 |
2022-12-01 |
Shape Therapeutics Inc. |
High throughput engineering of functional AAV capsids
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
EP4171738A1
(en)
|
2020-06-17 |
2023-05-03 |
The Trustees of The University of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
|
US20230242905A1
(en)
*
|
2020-07-03 |
2023-08-03 |
Genethon |
Method for Engineering Novel Hybrid AAV Capsids Through Hyper Variable Regions Swapping
|
|
EP4179091A1
(en)
|
2020-07-10 |
2023-05-17 |
Institut National De La Sante Et De La Recherche Medicale - Inserm |
Methods and compositions for treating epilepsy
|
|
CN116438311A
(zh)
|
2020-07-13 |
2023-07-14 |
宾夕法尼亚州大学信托人 |
可用于治疗夏科-马里-图思病的组合物
|
|
WO2022026409A1
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
CN115927398B
(zh)
*
|
2020-07-29 |
2024-11-19 |
北京三诺佳邑生物技术有限责任公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
|
CN116323953A
(zh)
|
2020-07-30 |
2023-06-23 |
沙普治疗股份有限公司 |
诱导产生raav病毒粒子的稳定细胞系
|
|
EP4200429A1
(en)
|
2020-08-24 |
2023-06-28 |
The Trustees of The University of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
|
US20230364264A1
(en)
|
2020-08-26 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
US20250326861A1
(en)
|
2020-09-15 |
2025-10-23 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
CA3194861A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as gel formulations
|
|
US20240024508A1
(en)
|
2020-10-07 |
2024-01-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
|
EP4225381A1
(en)
|
2020-10-07 |
2023-08-16 |
RegenxBio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
|
IL301643A
(en)
|
2020-10-07 |
2023-05-01 |
Regenxbio Inc |
Gene therapy for ocular manifestations of CLN2 disease
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
CA3193697A1
(en)
|
2020-10-07 |
2022-04-14 |
Joseph Bruder |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
CA3193833A1
(en)
|
2020-10-09 |
2022-04-14 |
Juliette HORDEAUX |
Compositions and methods for treatment of fabry disease
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
CA3195553A1
(en)
|
2020-10-18 |
2022-04-21 |
Qiang Wang |
Improved adeno-associated virus (aav) vector and uses therefor
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
AR123948A1
(es)
|
2020-10-28 |
2023-01-25 |
Regenxbio Inc |
ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
EP4237453A1
(en)
|
2020-10-29 |
2023-09-06 |
RegenxBio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
MX2023006445A
(es)
|
2020-12-01 |
2023-08-10 |
Univ Pennsylvania |
Composiciones y usos de estas para el tratamiento del síndrome de angelman.
|
|
WO2022119839A1
(en)
|
2020-12-01 |
2022-06-09 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
|
US20240024507A1
(en)
|
2020-12-01 |
2024-01-25 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
|
KR20230120128A
(ko)
|
2020-12-16 |
2023-08-16 |
리젠엑스바이오 인크. |
재조합 바이러스 입자의 생산 방법
|
|
US20240139344A1
(en)
|
2020-12-29 |
2024-05-02 |
Akouos, Inc. |
Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
|
|
WO2022147087A1
(en)
|
2020-12-29 |
2022-07-07 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
|
EP4277933A4
(en)
|
2021-01-14 |
2024-12-11 |
Senti Biosciences, Inc. |
SECRETABLE PAYLOAD REGULATION
|
|
CA3205209A1
(en)
|
2021-01-21 |
2022-07-28 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
|
CA3209779A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
US11926842B2
(en)
|
2021-02-02 |
2024-03-12 |
University Of Massachusetts |
Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors
|
|
EP4291249A2
(en)
|
2021-02-10 |
2023-12-20 |
RegenxBio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
|
TW202302855A
(zh)
|
2021-02-26 |
2023-01-16 |
日商武田藥品工業股份有限公司 |
用於治療法布瑞氏症之組成物及方法
|
|
AU2022258312A1
(en)
|
2021-04-12 |
2023-10-26 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating spinal and bulbar muscular atrophy (sbma)
|
|
AR125406A1
(es)
|
2021-04-23 |
2023-07-12 |
Univ Pennsylvania |
Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
|
|
MX2023012511A
(es)
|
2021-04-23 |
2024-01-08 |
Univ Rochester |
Edición del genóma por inserción no homóloga de adn dirigida utilizando una proteína de fusión retroviral de integrasa-cas y métodos de tratamiento.
|
|
TW202309293A
(zh)
|
2021-04-26 |
2023-03-01 |
美商銳進科斯生物股份有限公司 |
用於治療肌縮蛋白症(dystrophinopathy)之微小肌縮蛋白基因療法給藥
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
WO2022241030A1
(en)
|
2021-05-11 |
2022-11-17 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
WO2022272297A1
(en)
|
2021-06-25 |
2022-12-29 |
Oxford Biomedica Solutions Llc |
Adeno-associated virus packaging systems
|
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
EP4373947A1
(en)
|
2021-07-19 |
2024-05-29 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
JP2024534771A
(ja)
|
2021-08-11 |
2024-09-26 |
サナ バイオテクノロジー，インコーポレイテッド |
補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
|
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
MX2024001208A
(es)
|
2021-08-11 |
2024-04-22 |
Sana Biotechnology Inc |
Celulas primarias geneticamente modificadas para terapia celular alogenica.
|
|
US20250019721A1
(en)
|
2021-08-11 |
2025-01-16 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for treating a muscular dystrophy
|
|
EP4392016A1
(en)
|
2021-08-24 |
2024-07-03 |
Oxford Biomedica (US) LLC |
Adeno-associated virus formulations
|
|
CN118159663A
(zh)
*
|
2021-08-25 |
2024-06-07 |
北海康成制药有限公司 |
包含嗜肝衣壳蛋白和酸性α-葡糖苷酶（GAA）的AAV颗粒及其治疗庞贝病的用途
|
|
WO2023034880A2
(en)
|
2021-08-31 |
2023-03-09 |
Scout Bio, Inc. |
Antigen-binding molecules and uses thereof
|
|
US20250288692A1
(en)
|
2021-09-30 |
2025-09-18 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
US20240384298A1
(en)
|
2021-10-02 |
2024-11-21 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
EP4413018A1
(en)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
WO2023072181A1
(en)
*
|
2021-10-28 |
2023-05-04 |
Shanghai Vitalgen Biopharma Co., Ltd. |
Adeno-associated virus capsid
|
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
US20230183658A1
(en)
|
2021-10-29 |
2023-06-15 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the purification of adeno-associated virus
|
|
US20250295807A1
(en)
|
2021-11-15 |
2025-09-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
US20250051750A1
(en)
|
2021-11-29 |
2025-02-13 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
WO2023102078A2
(en)
|
2021-12-01 |
2023-06-08 |
Shape Therapeutics Inc. |
Functional aav capsids for intravitreal administration
|
|
JP2024543211A
(ja)
|
2021-12-01 |
2024-11-19 |
シェイプ セラピューティクス インコーポレイテッド |
全身投与用の機能的ａａｖカプシド
|
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
CN118510905A
(zh)
*
|
2021-12-06 |
2024-08-16 |
学校法人顺天堂 |
改变型腺伴随病毒载体
|
|
WO2023114901A2
(en)
|
2021-12-15 |
2023-06-22 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the production of adeno-associated virus
|
|
AR128239A1
(es)
|
2022-01-10 |
2024-04-10 |
Univ Pennsylvania |
Composiciones y métodos útiles para el tratamiento de trastornos mediados por c9orf72
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
|
MX2024009186A
(es)
|
2022-01-25 |
2024-09-30 |
Univ Pennsylvania |
Cápsides de aav para mejorar la transducción cardiaca y desdireccionamiento del hígado.
|
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
AU2023215253A1
(en)
|
2022-02-02 |
2024-09-19 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
|
AU2023220128A1
(en)
|
2022-02-17 |
2024-08-22 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
AU2023220237A1
(en)
|
2022-02-21 |
2024-08-15 |
Shanghai Regenelead Therapies Co., Ltd |
Vegf-binding molecule and pharmaceutical use thereof
|
|
EP4490278A1
(en)
|
2022-03-07 |
2025-01-15 |
Ultragenyx Pharmaceutical Inc. |
Modified batch aav production systems and methods
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
|
EP4499154A1
(en)
|
2022-03-25 |
2025-02-05 |
REGENXBIO Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
US20250213730A1
(en)
|
2022-04-01 |
2025-07-03 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
|
EP4504258A1
(en)
|
2022-04-06 |
2025-02-12 |
The Trustees of the University of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
|
EP4504149A1
(en)
|
2022-04-06 |
2025-02-12 |
RegenxBio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoidal administration
|
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
|
CN119317645A
(zh)
|
2022-04-06 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于治疗her2阳性转移性乳腺癌及其他癌症的组合物和方法
|
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
|
EP4507741A1
(en)
|
2022-04-14 |
2025-02-19 |
RegenxBio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
US20250288697A1
(en)
|
2022-05-03 |
2025-09-18 |
Regenxbio Inc. |
Vectorized anti-tnf-alpha inhibitors for ocular indications
|
|
AR129215A1
(es)
|
2022-05-03 |
2024-07-31 |
Regenxbio Inc |
Anticuerpos anti-complemento y agentes del complemento vectorizados y administración de estos
|
|
JP2025517628A
(ja)
|
2022-05-06 |
2025-06-10 |
ノバルティス アーゲー |
新規の組換えａａｖ ｖｐ２融合ポリペプチド
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
CN119731321A
(zh)
|
2022-06-24 |
2025-03-28 |
图恩疗法股份有限公司 |
通过靶向基因阻遏减少低密度脂蛋白的组合物、系统和方法
|
|
CA3259982A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
|
|
EP4558149A1
(en)
|
2022-07-21 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
JP2025527658A
(ja)
|
2022-08-24 |
2025-08-22 |
リジェネックスバイオ インコーポレイテッド |
組換えアデノ随伴ウイルス及びその使用
|
|
JP2025529884A
(ja)
|
2022-08-25 |
2025-09-09 |
武田薬品工業株式会社 |
ファブリー病の治療に使用するための組成物
|
|
IL319873A
(en)
|
2022-09-30 |
2025-05-01 |
Regenxbio Inc |
Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
|
|
CN115960177B
(zh)
*
|
2022-10-09 |
2023-07-07 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
EP4601710A2
(en)
|
2022-10-11 |
2025-08-20 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
CN117304256B
(zh)
*
|
2022-12-08 |
2024-04-16 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
AU2023398931A1
(en)
|
2022-12-17 |
2025-07-10 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
IT202200026595A1
(it)
|
2022-12-22 |
2024-06-22 |
Fond Telethon Ets |
Nuovi inibitori di regolatori epigenetici
|
|
EP4646478A1
(en)
|
2023-01-06 |
2025-11-12 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024192281A2
(en)
|
2023-03-15 |
2024-09-19 |
Regenxbio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
US20240401025A1
(en)
|
2023-05-03 |
2024-12-05 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024229302A1
(en)
|
2023-05-03 |
2024-11-07 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2024241176A1
(en)
|
2023-05-24 |
2024-11-28 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders
|
|
WO2024258961A1
(en)
|
2023-06-12 |
2024-12-19 |
The Trustees Of The University Of Pennsylvania |
Aav gene therapy for mucopolysaccharidosis iiib
|
|
TW202516019A
(zh)
|
2023-06-29 |
2025-04-16 |
賓州大學委員會 |
具中樞神經系統靶向模體的突變aav及含有其之組成物
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
WO2025035143A1
(en)
|
2023-08-10 |
2025-02-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of spinal muscular atrophy
|
|
WO2025075963A1
(en)
|
2023-10-02 |
2025-04-10 |
Regenxbio Inc. |
Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase
|
|
WO2025082618A1
(en)
|
2023-10-20 |
2025-04-24 |
Fuse Vectors Aps |
In vitro parvovirus capsid manufacturing
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025188625A1
(en)
|
2024-03-03 |
2025-09-12 |
Passage Bio, Inc. |
Recombinant adeno-associated virus for treatment of neurodegenerative disorders
|
|
WO2025188755A1
(en)
|
2024-03-04 |
2025-09-12 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
CN118460614B
(zh)
*
|
2024-07-05 |
2025-03-11 |
凌意(杭州)生物科技有限公司 |
一种腺相关病毒Cap蛋白的表达框
|
|
CN118754952B
(zh)
*
|
2024-09-06 |
2025-01-10 |
上海玮美基因科技有限责任公司 |
一种新型腺相关病毒及其应用
|